Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Americans 'Hostages' To 'Ransom' Drug Prices, Senators Charge

This article was originally published in Scrip

Executive Summary

Drug companies like Turing Pharmaceuticals AG and Valeant Pharmaceuticals International Inc., which have significantly raised the prices of their older, off-patent drugs, were accused on Dec. 9 by lawmakers of holding American patients hostage for ransom – a situation some members of Congress argued needs to be controlled through price regulations, like those used to rein in the railroad, electric utilities and telephone industries.

You may also be interested in...



Clinton's Plan To Tame 'Unjustified' Drug Prices: Who's At Risk?

It's uncertain whether Democratic presidential candidate Hillary Clinton's attempt at drug pricing reform would be viable, but it's one analysts say to take seriously because the first step could lead to more.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Allergan's Price Reform Pledge: Will Others Follow?

Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel